Daniel Gilbert

Washington, D.C.

Reporter covering the business of medicine

Education: University of Chicago, BA in International Studies

Daniel Gilbert joined The Washington Post in 2022 and writes about the business of medicine. He previously spent seven years as an investigative reporter for the Seattle Times, and before that covered business and energy for the Wall Street Journal in Houston. As a staff writer for the Bristol Herald Courier in Bristol, Va., his reporting on Virginia’s mismanagement of natural-gas royalties received the 2010 Pulitzer Prize for Public Service.
Latest from Daniel Gilbert

Biden administration names 10 prescription drugs for price negotiations

The move represents an unprecedented step in a long political war over the nation’s exorbitant drug costs.

August 29, 2023

As drugmakers slam Medicare price controls, Wall Street shrugs

Drugmakers unleashed a broadside at the Inflation Reduction Act, but most will see minimal impacts from price caps — for now.

August 29, 2023

Opioid-maker Mallinckrodt’s bankruptcy will cut nearly $1 billion from settlement

Drug maker Mallinckrodt, on the hook for more than $1 billion in opioid settlement payments, plans to file for bankruptcy for a second time. The move imperils the $1.7 billion opioid settlement struck last year.

August 23, 2023

Brain chip helps voiceless patient communicate at 62 words per minute

Using brain implants, machine learning and a predictive model, researchers decoded a woman’s attempts to speak at a rate that begins to approach natural conversation.

August 23, 2023

How troubles at a factory in India led to a U.S. cancer-drug shortage

Intas Pharmaceuticals in India made a widely used cancer drug in the U.S. An inspection exposed problems — and the fragility of the U.S. generic-drug supply.

June 27, 2023

Pfizer picks its pill in race for Ozempic-like weight-loss drug

Pfizer will move ahead with a pill version of a weight-loss drug as competition heats up for an oral medication that can rival Ozempic and other GLP-1 drugs.

June 26, 2023

Insurers clamping down on doctors who prescribe Ozempic for weight loss

Weight-loss drugs known as GLP-1s have created a frenzy among patients and investors, but the true size of the market may come down to how insurers cover the drugs.

June 12, 2023

McKinsey’s little-known role in the collapse of Silicon Valley Bank

The consulting firm was called out in the Fed report on SVB's collapse.

June 7, 2023

Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs

The first drug potentially covered by the expanded plan, Leqembi, could be granted full approval from the Food and Drug Administration as soon as this summer.

June 1, 2023

Elon Musk’s Neuralink says it has FDA approval for human trials: What to know

Neuralink said it has regulatory approval to conduct a clinical trial of its brain implants in people, a milestone for the company as it seeks to commercialize a device that will link human brains to computers.

May 26, 2023